Intensive high-dose chemotherapy with autologous stem-cell support has become a common treatment strategy for non-Hodgkin's lymphomas.
A cost-identification analysis was conducted comparing 10 patients autografted with PBSC to 10 others autografted with BM.
The analysis included harvest and graft until graft day+100 and was carried out from the point of view of the hospital setting.
Resources used, logistic and direct medical costs per patient were identified, and sensitivity analyses performed.
The cost distribution was different.
Stem cell harvest was more expensive for PBPC ($9030) and BM ($4745) ; on the other hand, hospitalization from graft to discharge from hospital cost savings with PBSC were about $10666.
After discharge from hospital, costs were similar and cheaper in both groups.
For the overall study the PBPC procedure was less expensive than ABMT, $35381 and $41759 respectively, with cost savings of $6378.
The number of days spent in hospital and blood bank costs were the major cost factors.
This study was based on a single pathology, non-Hodgkin's lymphoma, and the actual hospital records for each patient situation as opposed to a clinical trial, and our results were consistent with different previous studies carried out in different health care systems.
Mots-clés Pascal : Lymphome non hodgkinien, Autogreffe, Greffe, Cellule souche, Cellule hématopoïétique, Sang, Moelle osseuse, Analyse coût, Economie santé, Etude comparative, France, Europe, Traitement, Homme, Hémopathie maligne, Lymphoprolifératif syndrome, Transfusion
Mots-clés Pascal anglais : Non Hodgkin lymphoma, Autograft, Graft, Stem cell, Hematopoietic cell, Blood, Bone marrow, Cost analysis, Health economy, Comparative study, France, Europe, Treatment, Human, Malignant hemopathy, Lymphoproliferative syndrome, Transfusion
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0029040
Code Inist : 002B27D02. Création : 17/04/1998.